Compound comparison
Sermorelin vs. Tesamorelin: What the Trials Actually Found
Both stimulate the growth hormone pathway, but their evidence applies to different preparations and populations. Tesamorelin has an approved product for excess abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin has historical diagnostic and pediatric research, with additional adult research involving related GHRH analogs. Geref is no longer marketed; FDA found its withdrawal was not for safety or effectiveness reasons. This is not a head-to-head comparison, and these records do not establish a winner for general wellness.
Sermorelin
Compounding restrictedGHRH(1-29): the first 29 amino acids of growth hormone-releasing hormone, the shortest fragment that still triggers the pituitary.
Evidence strength: Randomized trials. Randomized controlled trials in humans, at scale.
Under active FDA restriction — compliant pharmacies decline to sell it.
Tesamorelin
FDA-approvedA synthetic analog of growth hormone-releasing hormone, given as a daily subcutaneous injection.
Evidence strength: Randomized trials. Randomized controlled trials in humans, at scale.
Approved for this use and available by prescription.
This is not a head-to-head trial
No head-to-head trial of these two compounds exists. A PubMed search in August 2026 restricted to the randomized-controlled-trial publication type returned zero records naming both, and the 12 papers that mention both are reviews of the growth hormone axis and doping-control assay methods rather than trials. Every row below therefore comes from a separate trial with its own population, its own duration and its own comparator: three of them in adults with HIV-associated lipodystrophy against placebo, two of them in children who were not growing, against injected growth hormone. Read the rows as five separate findings, not as a scored comparison with a winner.
What each trial reported
Every row is its own trial. Duration, sample size, and phase are shown next to every result on purpose — without them, a result is not a fact you can compare to anything.
| Compound | Trial | Population | Result | Duration | n | Phase | Status |
|---|---|---|---|---|---|---|---|
| Sermorelin | — | Children with growth hormone deficiency | Height velocity 9.2 and 9.3 cm/yr on two doses · 14.6 cm/yr on growth hormone | 26 wks | 60 | phase 2 | Compounding restricted |
| Sermorelin | — | Prepubertal children with growth hormone deficiency | Height velocity lowest on the low dose · comparable on the high dose and on growth hormone | 26 wks | 43 | phase 2 | Compounding restricted |
| Tesamorelin | Phase 3 (NCT00123253) | Adults with HIV-associated lipodystrophy | Visceral fat −15.2% · placebo +5.0% · IGF-1 +81.0% | 26 wks | 412 | phase 3 | FDA-approved |
| Tesamorelin | Two phase 3 trials, pooled | Adults on antiretroviral therapy with excess abdominal fat | Visceral fat −15.4% · subcutaneous fat −0.6%, not significant | 26 wks | 806 | phase 3 | FDA-approved |
| Tesamorelin | 26-week extension | Adults who continued tesamorelin for a second 26 weeks | Visceral fat −17.5% held at 52 wk · reaccumulated after stopping | 52 wks | 246 | phase 3 | FDA-approved |
Which has the clearer safety evidence?
Tesamorelin has an approved product label with trial adverse events and monitoring instructions. Sermorelin’s historical diagnostic and pediatric record does not provide an equivalent estimate for years of adult wellness treatment. More documented risks on one label do not show that the less-studied alternative is safer.
Egrifta WR’s label warns about elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity, and describes injection-site reactions. Those warnings apply to tesamorelin. Its event rates cannot be transferred to sermorelin, and this comparison cannot rank their tolerability without a relevant direct trial. 6
Geref’s discontinuation should also be described accurately: FDA determined that it was not withdrawn for safety or effectiveness reasons. That historical finding does not validate modern compounded preparations or an anti-aging indication. 7 For the practical limits of the evidence, see [sermorelin side effects](/peptides/sermorelin#sermorelin-side-effects-what-can-be-said-with-confidence).
The adult research needs a qualified reading
It is too broad to say that no older adult GHRH research measured body composition or sleep. A 1997 study of [Nle27]GHRH-(1-29)-NH2 included 19 older adults and sixteen weeks of active treatment after placebo. It reported increased lean mass in men only and skin thickness in both sexes; body weight and sleep quality were unchanged. This related-analog study does not establish every current sermorelin preparation or wellness claim. 8
Why the table has no winner
The pediatric sermorelin rows measure growth, whereas the tesamorelin rows measure abdominal fat in adults with HIV-associated lipodystrophy. Centimeters of growth and percentage changes in visceral fat answer different questions. Even identical endpoints from different trials would need attention to baseline risk, treatment duration and comparators before drawing a relative-effect conclusion. 1234
Tesamorelin’s phase 3 program and follow-up give a more developed evidence record for its specific approved indication. The extension research also examined continued treatment and discontinuation; findings about fat reaccumulation do not tell us what happens after stopping sermorelin used for a different purpose. 45
Approval concerns the finished product and indication
Geref is no longer marketed. FDA’s 2013 determination says its withdrawal was not for safety or effectiveness reasons. Egrifta WR has a current tesamorelin label for a specific HIV-associated condition. Neither fact approves all compounded versions or converts these medicines into general weight-loss or anti-aging treatments. 67
If a clinician proposes either treatment, ask which evidence applies to your diagnosis and exact preparation, how benefit will be assessed and which monitoring is planned. The sermorelin evidence page and tesamorelin review discuss each record in more detail.
Frequently asked questions
Is tesamorelin proven better than sermorelin?
The separate trials listed here cannot establish that. They studied different populations and outcomes; there is no relevant head-to-head result in the evidence reviewed.
Is sermorelin safer because it has fewer listed warnings?
Fewer documented events in a smaller evidence base do not establish greater safety. Tesamorelin label rates must not be copied to sermorelin.
Was Geref withdrawn for safety reasons?
No. FDA determined in 2013 that the discontinued Geref presentations were not withdrawn for safety or effectiveness reasons. This does not approve current compounded preparations.
References
- Chen RG, Shen YN, Yei J, et al. (1993). A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatrica Supplement. https://pubmed.ncbi.nlm.nih.gov/8329830/
- Neyzi O, Yordam N, Ocal G, et al. (1993). Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatrica Supplement. https://pubmed.ncbi.nlm.nih.gov/8329826/
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Falutz J, Mamputu JC, Potvin D, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Falutz J, Allas S, Mamputu JC, et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. https://pubmed.ncbi.nlm.nih.gov/18690162/
- Theratechnologies / DailyMed (2025). EGRIFTA WR (tesamorelin) prescribing information. Theratechnologies / DailyMed; accessed October 13, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
- US Food and Drug Administration (2013). Determination that GEREF was not withdrawn from sale for reasons of safety or effectiveness. US Food and Drug Administration; accessed October 13, 2026. https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm
- Khorram O, Laughlin GA, Yen SS (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/9141536/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.